> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Windward Bio Secures Sanofi’s $50 Million Commitment Alongside Its Pending IPO
- URL: https://www.bullished.co/windward-bio-secures-sanofis-50-million-commitment-alongside-its-pending-ipo-e5cf0687/
- Published: 2026-11-09T11:41:13.000Z
- Updated: 2026-11-09T11:41:13.000Z
- Description: The Swiss drug developer proposes 10,294,117 IPO shares as it funds antibody trials for respiratory and skin diseases.
- Author: Matteo Parrino
- Tags: Deals, Industry: Not classified

Windward Bio, a Swiss biotechnology company developing antibody drugs for respiratory and skin diseases, secured a [$50.0 million commitment](https://www.sec.gov/Archives/edgar/data/0002145089/000119312526452536/d111653df1a.htm?ref=bullished.co) from Sanofi Monday alongside its pending IPO, according to an amended SEC registration statement. The investment depends on the IPO closing; the public offering can proceed without Sanofi’s purchase.

## Sanofi Buys Shares And Prepaid Rights

Sanofi Foreign Participations would buy 1,532,691 common shares plus prepaid rights covering 1,408,485 additional shares, using the proposed offering’s $17.00 midpoint. The common-share count is fixed, while the number covered by the rights will change with final pricing; exercising those rights requires no further payment.

Windward expects approximately $48.2 million from the separate investment after expenses. The prepaid rights carry no voting rights until exercised, and initially cannot be exercised if doing so would take the holder’s combined ownership above 4.99%.

The public offering now specifies 10,294,117 shares at a proposed $16.00–$18.00 each. Those counts reflect a 3-for-2 reverse split approved Thursday and effective Friday. Windward has applied for a Nasdaq Global Market listing under WWB, with Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank selling the offering.

## Fundraising Supports A Revenue-Free Business

Windward has raised $310.0 million through equity financing and has generated no revenue. Management’s preliminary, unaudited estimate puts cash, cash equivalents and marketable securities at approximately $181.8 million on September 30, 2026.

The company’s financing plans also include a waived commitment: Series B investors relinquished their obligation on October 30 to fund a $55.0 million second tranche. Those investors may participate in the IPO.

Research and development expenses reached $30.133 million in the first six months of 2026, versus $13.325 million a year earlier. Windward expects additional funding needs even if both the IPO and Sanofi investment succeed.

IPO-linked option awards for certain directors, executives, employees and consultants would cover approximately 2,390,010 shares. The final count depends on agreed ownership targets and the offering’s terms, creating another potential source of new shares beyond the public offering and Sanofi purchase.

## Antibody Trials Drive The Spending Plan

Windward intends to combine the new financing with existing cash to spend approximately $217.5 million–$227.5 million on WIN378 trials and related development, according to its [spending plan](https://www.sec.gov/Archives/edgar/data/0002145089/000119312526452536/d111653df1a.htm?ref=bullished.co). Another approximately $80 million–$85 million would support WIN027 trials and related work, with approximately $5 million–$10 million for earlier antibody programs.

WIN378 targets TSLP, a protein involved in inflammation, and is being tested for severe uncontrolled asthma and chronic obstructive pulmonary disease. Windward believes its extended action could support twice-yearly injections; the late-stage portion of its asthma study began in September 2026.

WIN027 targets both TSLP and IL-13, another inflammatory protein. Windward plans mid-stage studies in chronic obstructive pulmonary disease and atopic dermatitis, with patient recruitment expected in the first half of 2027\. Early results may not predict later trial outcomes, the company cautions.

Windward expects primary results from the mid-stage portion of its WIN378 asthma trial and full results from its early-stage WIN027 study in the first half of 2027.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [F-1/A — WINDWARD BIO GROUP AG](https://www.sec.gov/Archives/edgar/data/0002145089/000119312526452536/d111653df1a.htm?ref=bullished.co) — SEC EDGAR